HUNTINGTON BEACH, California and AMSTERDAM, April 20, 2010
(ots/PRNewswire) -- Agendia, a world leader in molecular cancer
diagnostics, announced today it has closed an agreement with Ferrer
inCode for the commercialization of Agendia's FDA-cleared breast
cancer recurrence test MammaPrint in Latin America.
For the successful commercialization of MammaPrint, Ferrer inCode
will leverage the distribution power of its mother company Grupo
Ferrer Internacional, the leading Spanish pharmaceutical company in
Latin America. Ferrer products are sold in 18 Latin American
countries through subsidiaries, joint ventures and independent
distributors. In key markets such as Brazil, Argentina, Venezuela,
and Peru, Ferrer is ranked either first or second in terms of
"Capitalizing on Ferrer inCode's dominant position on the Iberian
peninsula, we are delighted to expand our strong partnership and make
MammaPrint available to doctors and patients in Latin America as
well," said Bas van der Baan, Vice President Commercial Operation
Europe/ROW of Agendia. "Ferrer has a strong presence in most of the
Latin American key markets, most notably in rapidly emerging
countries such as Brazil and Argentina, and has made great strides
towards reimbursement in a number of Latin American countries."
MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA
clearance under the in vitro diagnostic multivariate index assay
(IVDMIA) guidelines requires clinical and analytical validation and
reporting systems to ensure patient safety issues are addressed.
Highly accurate, MammaPrint identifies patients with early metastasis
risk - patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test results provide doctors with
a clear rationale to assess the benefit of chemotherapy in addition
to other clinical information and pathology tests.
All MammaPrint tests are conducted in Agendia's CAP-accredited
and CLIA compliant service laboratories. Breast cancer recurrence
assays currently marketed by other manufacturers have not been
subject to the rigorous FDA clearance process.
Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting-edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. Agendia is based in Huntington Beach, California, and
in Amsterdam, The Netherlands.
About Ferrer inCode
Ferrer inCode is the biotech subsidiary of Grupo Ferrer
Internacional, focused on personalized medicine by providing
diagnostic orientation, prognosis and prediction services based on
genomics, proteomics, metabolomics and bioinformatics platforms. The
vision of Ferrer inCode is to help doctors make the most accurate
clinical decisions for each patient through advanced biotechnological
services. Ferrer is a privately held European R&D-based
pharmaco-chemical and medical device company headquartered in
Barcelona, Spain. Ferrer is the third largest Spanish pharma company
in Spain, with sales and distribution in over 90 countries.
ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.ch
CONTACT: MEDIA CONTACTS: Hans Herklots, Head of Corporate
Communications,Agendia, +31-20-462-1557 Office, +31-620-083-509
Mobile,email@example.com; Valerie Delva, Account Executive,
RicochetPublic Relations, +1-212-679-3300 x131 Office,
firstname.lastname@example.org; OlgaFidalgo, Corporate Director, Business
Development & Licensing, Grupo FerrerInternacional, +34-93-600-37-00
Switchboard, +34-93-600-38-67 Office,email@example.com